Coherus Biosciences Inc  

(Public, NASDAQ:CHRS)   Watch this stock  
Find more results for CHRS
+0.24 (1.00%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.16 - 24.33
52 week 12.04 - 37.02
Open 24.19
Vol / Avg. 0.00/421,448.00
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -6.43
Shares 42.64M
Beta     -
Inst. own 65%
Aug 3, 2016
Q2 2016 Coherus BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 11, 2016
Coherus BioSciences Inc Announces Positive Topline Results for CHS-1701
Jun 28, 2016
Coherus BioSciences Inc Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis Conference Call
Jun 8, 2016
Coherus BioSciences Inc at Jefferies Healthcare Conference
May 24, 2016
Coherus BioSciences Inc Annual Shareholders Meeting
May 11, 2016
Coherus BioSciences Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 9, 2016
Q1 2016 Coherus BioSciences Inc Earnings Call - Webcast
May 9, 2016
Q1 2016 Coherus BioSciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -530.29% -745.44%
Operating margin -520.69% -729.23%
EBITD margin - -722.90%
Return on average assets -119.86% -112.08%
Return on average equity - -736.90%
Employees 115 -
CDP Score - -


333 Twin Dolphin Dr Ste 600
REDWOOD CITY, CA 94065-1442
United States - Map
+1-650-6493530 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Officers and directors

James M. Daly Executive Chairman of the Board
Bio & Compensation  - Reuters
Dennis M. Lanfear President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Jean-Frederic Viret Ph.D. Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Peter K. Watler Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Alan C. Herman Ph.D. Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
Barbara K. Finck M.D. Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Christos Richards Director
Age: 57
Bio & Compensation  - Reuters
August J. Troendle M.D. Director
Age: 58
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters